JP4997432B2 - 神経幹細胞の増殖抑制剤 - Google Patents
神経幹細胞の増殖抑制剤 Download PDFInfo
- Publication number
- JP4997432B2 JP4997432B2 JP2006034444A JP2006034444A JP4997432B2 JP 4997432 B2 JP4997432 B2 JP 4997432B2 JP 2006034444 A JP2006034444 A JP 2006034444A JP 2006034444 A JP2006034444 A JP 2006034444A JP 4997432 B2 JP4997432 B2 JP 4997432B2
- Authority
- JP
- Japan
- Prior art keywords
- neural stem
- stem cells
- galectin
- integrin
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Description
Van-der-Kooy and Weiss, Science 287:1439-1441 (2000) Fuchsand Segre, Cell 100:143-55 (2000) Seaberg and van-der-Kooy J Neurosci. 22:1784-1793 (2002) Wu et al., Neurosci Lett. 312:173-176 (2001) Gage et al., Proc Natl Acad Sci U S A 92:11879-11883 (1995) Fricker et al., J Neurosci. 19:5990-6005 (1999) Akiyama et al., Exp Neurol. 167:27-39 (2001) Bajocchi et al., Nat Genet. 3:229-234 (1993) Araujo and Hilt Neuroscience 81:1099-110 (1997) Bai et al. J Neurosci Methods 124:181-187 (2003)
参考実験に示すように、ガレクチン−1が神経幹細胞の増殖を促進する際、インテグリンβ1を受容体とし、神経幹細胞にシグナルを伝達する。そこで、ガレクチン−1に対する結合阻害活性を有する抗インテグリンβ1抗体などの、ガレクチン−1とインテグリンβ1との結合を阻害する結合阻害組成物を投与することにより、ガレクチン−1から神経幹細胞への増殖シグナルが遮断され、神経幹細胞の増殖が抑制される。
このように、ガレクチン−1とインテグリンβ1との結合を阻害する結合阻害組成物を神経幹細胞に作用させると、神経幹細胞の増殖を抑制することができる。
上記のように、ラットの第四脳室内の脳脊髄液に神経幹細胞を注入すると、細胞自らが損傷部を認識し、損傷部に入り込んで修復に関与することが示されている(例えば、上記非特許文献10参照)。しかしながら、移植した神経幹細胞の増殖は1年以上も止まらない。このような場合に、本発明に従って、ガレクチン−1とインテグリンβ1との結合を阻害する結合阻害組成物を投与することにより、神経幹細胞の増殖を抑制することができる。
悪性腫瘍とは、1)正常の分化能力を失った細胞が 2)自己複製能力を獲得し異常に増殖することにより、正常細胞を駆逐してしまう病態である。
神経幹細胞に対するガレクチン−1の結合に糖が関与しているかどうかを調べるため、ビオチン化C2Sガレクチン−1(C2S-GAL-1-bio)(産総研より提供)を用いて、ラクトースの存在下で組織染色を行った。このC2S-GAL-1は、ガレクチン−1の2番目のシステインをセリンに置換した変異体(Hirabayashi & Kasai, J Biol Chem 266, 23648-23653 1991)で、正常な炭化水素結合能を有することが既に示されている(Purkrabkova et al. Biol Cell 95, 535-545, 2003)。
SVZにおいては、SVZアストロサイトの一部は神経幹細胞として機能し、中間分化段階のTA細胞(transit amplifying cells)を経て、さらに細胞増殖の後、NB(神経芽細胞)へと分化することが知られている。この神経幹細胞は、比較的ゆっくり増殖することが知られているため、長期的にBrdUを取り込ませることにより、神経幹細胞を同定することができる。
Claims (4)
- 抗インテグリンβ1抗体を含有する、神経幹細胞の増殖抑制剤。
- 請求項1に記載の増殖抑制剤を含有する神経損傷治療剤であって、神経損傷を有し、神経幹細胞が投与される脊椎動物に投与され、前記投与された神経幹細胞の増殖を抑制する、神経損傷治療剤。
- 脳脊髄液に投与されることを特徴とする、請求項2に記載の神経損傷治療剤。
- 抗インテグリンβ1抗体を含有する、抗神経腫瘍剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006034444A JP4997432B2 (ja) | 2006-02-10 | 2006-02-10 | 神経幹細胞の増殖抑制剤 |
US11/704,185 US7662385B2 (en) | 2006-02-10 | 2007-02-09 | Agent for inhibiting proliferation of neural stem cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006034444A JP4997432B2 (ja) | 2006-02-10 | 2006-02-10 | 神経幹細胞の増殖抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007210968A JP2007210968A (ja) | 2007-08-23 |
JP4997432B2 true JP4997432B2 (ja) | 2012-08-08 |
Family
ID=38489722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006034444A Expired - Fee Related JP4997432B2 (ja) | 2006-02-10 | 2006-02-10 | 神経幹細胞の増殖抑制剤 |
Country Status (2)
Country | Link |
---|---|
US (1) | US7662385B2 (ja) |
JP (1) | JP4997432B2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7909043B2 (en) * | 2005-05-06 | 2011-03-22 | Avon Products, Inc. | Brush for applying a cosmetic product |
JP4925262B2 (ja) * | 2006-04-05 | 2012-04-25 | 学校法人慶應義塾 | シグナル伝達系活性化剤 |
BRPI0721929B1 (pt) * | 2007-08-13 | 2018-11-27 | Sumitomo Chemical Co | grânulo revestido com resina de uretano |
WO2012129448A1 (en) | 2011-03-23 | 2012-09-27 | The Regents Of The University Of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
US20210138080A1 (en) | 2018-06-29 | 2021-05-13 | Glykos Biomedical Oy | Conjugates |
WO2021123506A1 (en) | 2019-12-18 | 2021-06-24 | Glykos Biomedical Oy | Stabile conjugate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7785596B2 (en) * | 2003-09-09 | 2010-08-31 | Keio University | Methods for enhancing survival and/or proliferation of neural stem cells and neurite extension enhancers therefor pharmaceutical compositions containing neural stem cells assay methods and screening methods |
-
2006
- 2006-02-10 JP JP2006034444A patent/JP4997432B2/ja not_active Expired - Fee Related
-
2007
- 2007-02-09 US US11/704,185 patent/US7662385B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7662385B2 (en) | 2010-02-16 |
US20070248592A1 (en) | 2007-10-25 |
JP2007210968A (ja) | 2007-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Arotcarena et al. | Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies | |
AU2019201337B2 (en) | Methods and compositions for treating aging-associated impairments | |
Borroni et al. | Smurf2 regulates stability and the autophagic–lysosomal turnover of lamin A and its disease‐associated form progerin | |
Suwanabol et al. | TGF-β and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells | |
Cristante et al. | Identification of an essential endogenous regulator of blood–brain barrier integrity, and its pathological and therapeutic implications | |
Zhu et al. | Inhibiting cell cycle progression reduces reactive astrogliosis initiated by scratch injury in vitro and by cerebral ischemia in vivo | |
Zhan et al. | Upregulation of neuronal zinc finger protein A20 expression is required for electroacupuncture to attenuate the cerebral inflammatory injury mediated by the nuclear factor-kB signaling pathway in cerebral ischemia/reperfusion rats | |
Thoppil et al. | Senolytics: a translational bridge between cellular senescence and organismal aging | |
Wu et al. | TNF induces caspase-dependent inflammation in renal endothelial cells through a Rho-and myosin light chain kinase-dependent mechanism | |
Valera et al. | MicroRNA-101 modulates autophagy and oligodendroglial alpha-synuclein accumulation in multiple system atrophy | |
Van Dijk et al. | Intravenous clusterin administration reduces myocardial infarct size in rats | |
Li et al. | Expression and cell distribution of receptor for advanced glycation end-products in the rat cortex following experimental subarachnoid hemorrhage | |
Sahin et al. | The cell survival kinase SGK 1 and its targets FOXO 3a and NDRG 1 in aged human brain | |
JP4997432B2 (ja) | 神経幹細胞の増殖抑制剤 | |
Wang et al. | BDNF inhibits neurodegenerative disease–associated asparaginyl endopeptidase activity via phosphorylation by AKT | |
Cui et al. | KLF 4 Knockdown Attenuates TBI‐Induced Neuronal Damage through p53 and JAK‐STAT 3 Signaling | |
Naikawadi et al. | A Critical Role for Phosphatidylinositol (3, 4, 5)-Trisphosphate–Dependent Rac Exchanger 1 in Endothelial Junction Disruption and Vascular Hyperpermeability | |
Xie et al. | Netrin‐1 preserves blood‐brain barrier integrity through deleted in Colorectal Cancer/Focal Adhesion kinase/RhoA signaling pathway following subarachnoid hemorrhage in rats | |
Chen et al. | Propofol improved hypoxia‐impaired integrity of blood‐brain barrier via modulating the expression and phosphorylation of zonula occludens‐1 | |
Fang et al. | The adhesion and migration of microglia to β-amyloid (Aβ) is decreased with aging and inhibited by Nogo/NgR pathway | |
Martin et al. | VEGF counteracts amyloid-β-induced synaptic dysfunction | |
Sagy‐Bross et al. | The role of cytosolic phospholipase A2α in amyloid precursor protein induction by amyloid beta1‐42: implication for neurodegeneration | |
Feng et al. | Aβ induces PUMA activation: a new mechanism for Aβ-mediated neuronal apoptosis | |
Wang et al. | The intracellular domain of L1 CAM binds to casein kinase 2α and is neuroprotective via inhibition of the tumor suppressors PTEN and p53 | |
Li et al. | Astrocyte-derived TNF-α-activated platelets promote cerebral ischemia/reperfusion injury by regulating the RIP1/RIP3/AKT signaling pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111129 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120203 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120327 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120411 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4997432 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150525 Year of fee payment: 3 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |